CLINICAL ROLE -
Using Data to Optimize Use of CDK 4/6 Inhibitors for Metastatic HR+ Breast Cancer
Clinicians should consider the impact on subsequent therapies, overall survival, and median time to definitive deterioration with CDK 4/6 inhibitors.
Personalizing Breast Cancer Neoadjuvant and Adjuvant HER2-Targeted Therapy
Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.
Study Examines Use of Neoadjuvant Chemotherapy in Elderly Patients With Breast Cancer
The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.
